We work closely with academic founders and entrepreneurs to develop credible funding strategies to turn the best research into commercial success.
Parkwalk’s investment strategy is sector agnostic, investing across a broad range of sectors, which are of strategic importance to UK Plc, such as life sciences, quantum computing, advanced materials, genomics, cleantech, future of mobility, med-tech and big data. For example, Parkwalk were recently named the most active investor in Artificial Intelligence in the UK.
Given we are technology agnostic we generally seek to invest alongside specialist funds with the capacity to follow on investing in future rounds. We are the most co-invested fund in this asset class.
We are also stage / maturity agnostic, investing in Seed and Series C round and beyond. We have invested in up to five financing rounds of individual investee companies. We invest c. £65m per year in the sector.
Parkwalk actively seeks to co-invest with other specialist funds
We have the ability to invest from £250k to £10m per round
Invest from early-stage through to Series C round and beyond
Look to follow our money and invest over multiple rounds
Key Criteria 1
Key criteria for potential Parkwalk investee companies
- Businesses with strong links to a leading UK university or research establishment
- We generally require a potential investment to have come through a technology transfer or similar process
- The firm has a leading technology which has the potential for significant commercial success
- It has the ability to protect IP or know-how through, for example, patents and freedom to operate
- Have a suitable management team in place to provide appropriate leadership and governance
- We are an EIS Fund and so invest within those rules and restrictions.
- Our underlying investors will be looking to recycle their investment through a liquidity event in a 3-8 year period
Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.
Entia, a spin-out from Imperial College London, have developed novel ways of measuring blood counts to measure red cells, white cells and platelets and haemoglobin and haematocrit testing at home with results shared with healthcare professionals.
Oxford Endovascular is developing next-generation medical devices for neurovascular disease. The Company’s sophisticated metallic mesh tube devices and systems can be used to treat patients suffering from brain aneurysms. The tubes are made from a special metal alloy which has a shape memory and unfolds in the blood vessel when in place. The product and
Xeros Technologies developed innovative polymer-based technologies that allow industrial and commercial processes to be carried out using less water. It has built a stand alone commercial laundry business using the technology and has separate operations working in domestic laundry, leather processing, textile finishing and specialist uniform cleaning.